Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.61 |
| ▸ | LCK | P06239 | 5/20 | 0.61 |
| ▸ | KDR | P35968 | 5/20 | 0.61 |
| ▸ | CSF1R | P07333 | 3/20 | 0.61 |
| ▸ | EGFR | P00533 | 1/20 | 0.61 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.61 |
| ▸ | ABL1 | P00519 | 6/20 | 0.46 |
| ▸ | TEK | Q02763 | 2/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.45 |
| ▸ | LYN | P07948 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.45 |
| ▸ | RAF1 | P04049 | 7/20 | 0.45 |
| ▸ | BRAF | P15056 | 7/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2891119 | 0.83 | MAPK14 (0.53) | MAPK14LCKKDRCSF1REGFR | |
| SCHEMBL5494589 | 0.83 | LCK (0.65) | MAPK14LCKKDRTEKSRC | |
| SCHEMBL13198105 | 0.82 | MAPK14 (0.51) | MAPK14LCKKDRCSF1REGFR | |
| SCHEMBL13206946 | 0.81 | MAPK14 (0.51) | MAPK14LCKKDRCSF1REGFR | |
| SCHEMBL13198138 | 0.81 | MAPK14 (0.51) | MAPK14LCKKDRCSF1REGFR | |
| SCHEMBL13198056 | 0.81 | MAPK14 (0.65) | MAPK14LCKKDRCSF1REGFR | |
| SCHEMBL13198137 | 0.78 | LCK (0.50) | MAPK14LCKKDRCSF1REGFR | |
| SCHEMBL13198139 | 0.78 | MAPK14 (0.50) | MAPK14LCKKDRCSF1REGFR | |
| SCHEMBL13198008 | 0.78 | MAPK14 (0.59) | MAPK14LCKKDRCSF1REGFR | |
| SCHEMBL2883679 | 0.78 | DDR2 (0.70) | MAPK14LCKKDRCSF1REGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197688-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | MSD K.K. (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100197688-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | MSD K.K. (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100197688-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | MSD K.K. (JP) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197688-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | EPHA4, EPHA1, ERBB4 | MAPK14 146/4885LCK 140/4885KDR 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.